Global Postpartum Hemorrhage Treatment Devices Market – Industry Trends and Forecast to 2030

Global Postpartum Hemorrhage Treatment Devices Market, By Type (Uterine Balloon Tamponade, Uniject Prefilled Injection System, Non-Pneumatic Anti Shock Garment), End User (Hospitals, Clinics, Others) – Industry Trends and Forecast to 2030.

Postpartum Hemorrhage Treatment Devices Market Analysis and Size

The increasing prevalence of pregnancy-related complications such as large baby size, inverted uterus, and multiple pregnancies, among others, is a key driving factor for the development of the postpartum haemorrhage treatment devices market. Furthermore, various reasons for increased postpartum haemorrhage risk factors in pregnant women, such as increasing anemia cases, trauma, and uterine atony, among others, a key driving factor for the overall development of the postpartum haemorrhage treatment devices market.

Data Bridge Market Research analyses that the postpartum hemorrhage treatment devices market which was USD 772.60 million in 2022, is expected to reach USD 1009.53 million by 2030, at a CAGR of 3.4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Postpartum Hemorrhage Treatment Devices Market Scope and Segmentation  

Market Definition

The most common type of obstetric haemorrhage and one of the leading causes of maternal mortality is postpartum haemorrhage (PPH). PPH refers to blood loss during vaginal or cesarean delivery. The type of postpartum haemorrhage is determined by the amount of blood lost. Primary PPH is defined as blood loss of less than 500 mL, while secondary PPH has defined as blood loss greater than 500 mL.

Postpartum Hemorrhage Treatment Devices Market Dynamics

Drivers

• Rise in complications such as obstetric hemorrhage

The market for postpartum haemorrhage devices is expanding due to an increase in complications such as acute postpartum haemorrhage. Obstetric haemorrhage is the most common and dangerous complication of childbirth. PPH is traditionally defined as blood loss of more than 500 mL estimated during vaginal delivery or more than 1000 mL estimated during caesarean delivery. This was defined in 2017 by the American College of Obstetrics and Gynecology as an accumulation of blood loss of more than 1000 mL with signs and symptoms of hypovolemia within 24 hours of the birth procedure, regardless of delivery mode.

Opportunities

• Growing investment in healthcare sector in developed and developing countries

Governments in developing countries such as India and China invest heavily in their healthcare sectors. For example, the Indian health tech industry was estimated to be worth $1.9 billion in 2020. With a CAGR of 39%, it is expected to reach $ 5 billion by 2023. In 2018, the Indian digital healthcare market was valued at USD 1.50 billion, and it is expected to grow to USD 6.26 billion by 2024. The expansion of the healthcare industry is expected to benefit the postpartum haemorrhage devices market.

Restraints/Challenges

• Inaccuracies in measuring blood loss in obstetric Hemorrhage

Postpartum haemorrhage is the leading cause of maternal death in the United States, accounting for approximately 11% of all maternal deaths. Significantly, obstetric haemorrhage is responsible for 54-93% of maternal deaths. According to studies, healthcare providers' inaccurate estimation of actual blood loss at the time of birth and in the immediate postpartum period is a major cause of delayed haemorrhage response. Underestimation of blood loss leads healthcare providers to believe that deployment of postpartum haemorrhage devices is unnecessary, limiting the use of postpartum haemorrhage devices.

This postpartum hemorrhage treatment devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the postpartum hemorrhage treatment devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Postpartum Hemorrhage Treatment Devices Market

The COVID-19 pandemic had a negative impact on people's health and the global economy. It has affected entire economies, businesses, and individuals' careers and lives. Millions of people died as a result of the outbreak around the world. As businesses shift their focus away from growth prospects and toward implementing exceptional measures to mitigate the negative impact of the COVID-19 pandemic, the stress of maintaining pre-COVID revenue levels has become the new normal. The market for postpartum haemorrhage devices is expected to grow in response to the COVID-19 outbreak. Infection with Covid-19 increases the risk of pregnancy complications such as postpartum hemorrhage, which helps the market grow by increasing the number of PPH patients.

Recent Developments

• In 2021, Merck announced the acquisition of Alydia Health for its planned Organon spinoff, to improve women's health by addressing unmet medical needs in maternal health and facilitate safer delivery.
• In 2021, Stryker announced the acquisition of Gauss Surgical, a medical device company that developed TritonTM, an artificial intelligence-powered platform for real-time blood loss monitoring during surgery. Triton has demonstrated maternity and surgical care benefits by detecting haemorrhage and intervening sooner.

Global Postpartum Hemorrhage Treatment Devices Market Scope

The postpartum hemorrhage treatment devices market is segmented on the basis of type, end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Uterine Balloon Tamponade
• Foley Catheter
• Balloon Tamponade
• Condom Catheter
• Others
• Uniject Prefilled Injection System
• Non-Pneumatic Anti Shock Garment

End User

• Hospitals
• Clinics
• Others

Postpartum Hemorrhage Treatment Devices Market Regional Analysis/Insights

The postpartum hemorrhage treatment devices market is analyzed and market size insights and trends are provided by country, type, end-user as referenced above.

The countries covered in the postpartum hemorrhage treatment devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the postpartum hemorrhage treatment devices market because of the region's well-developed healthcare infrastructure and favourable reimbursement policies.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of haemorrhage.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The postpartum hemorrhage treatment devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for postpartum hemorrhage treatment devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the postpartum hemorrhage treatment devices market. The data is available for historic period 2011-2021.

Competitive Landscape and Postpartum Hemorrhage Treatment Devices Market Share Analysis

The postpartum hemorrhage treatment devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to postpartum hemorrhage treatment devices market.

Some of the major players operating in the postpartum hemorrhage treatment devices market are:

• BD (U.S.)
• General Electric (U.S.)
• BACTIGUARD AB (Sweden)
• Boen Healthcare Co., Ltd. (China)
• Cook (U.S.)
• RevMedx (U.S.)
• SARA HEALTH CARE (India)
• Inpress Technologies Inc. (U.S.)
• Vitality Medical (U.S.)
• Angiplast Pvt. Ltd. (India)
• Davol (India)
• 3rd Stone Design (U.S.)
• Teleflex Incorporated (U.S.)
• Utah Medical Products Inc. (U.S.)
• ZOEX (U.S.)